About Lucence diagnostics pte ltd
Lucence Diagnostics Pte Ltd: Revolutionizing Cancer Detection and Treatment with Liquid Biopsy Tests
Cancer is one of the deadliest diseases that affect millions of people worldwide. It is a complex disease that requires early detection and treatment to increase the chances of survival. However, traditional cancer diagnosis methods such as tissue biopsy are invasive, time-consuming, and often inaccurate. This is where Lucence Diagnostics Pte Ltd comes in with its revolutionary liquid biopsy tests.
Lucence Diagnostics Pte Ltd is a Singapore-based biotechnology company that specializes in developing ultrasensitive and non-invasive liquid biopsy tests for cancer detection and treatment. The company was founded in 2016 by Dr. Tan Min-Han, an oncologist who saw the need for better cancer diagnosis methods.
The company's mission is to make cancer diagnosis faster, more accurate, and less invasive by using cutting-edge technology such as next-generation sequencing (NGS) and artificial intelligence (AI). Lucence's liquid biopsy tests use a simple blood draw to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream.
What sets Lucence apart from other companies offering liquid biopsy tests is its proprietary technology called AmpliMARK™. This technology amplifies ctDNA or CTCs signals up to 10,000 times higher than other existing technologies on the market today. This means that Lucence's liquid biopsy tests can detect even small amounts of ctDNA or CTCs with high accuracy.
Lucence offers several types of liquid biopsy tests for different types of cancers such as lung cancer, breast cancer, colorectal cancer, liver cancer, pancreatic cancer, etc. These tests are designed to help doctors diagnose cancers at an early stage when they are still treatable.
One example of Lucence's innovative approach to cancer diagnosis is its LiquidHALLMARK® test for lung cancer detection. This test uses NGS technology combined with AI algorithms to analyze ctDNA mutations in the blood. The test can detect lung cancer with a sensitivity of 97% and a specificity of 99%, which is higher than traditional tissue biopsy methods.
Lucence's liquid biopsy tests are not only more accurate but also less invasive and faster than traditional cancer diagnosis methods. Patients can get their results within days instead of weeks or months, which is crucial for early detection and treatment.
Lucence has already made significant strides in the field of liquid biopsy tests for cancer diagnosis. The company has received several awards and recognitions such as the Frost & Sullivan Asia-Pacific Liquid Biopsy Diagnostics Technology Innovation Award in 2019.
In addition, Lucence has partnered with several leading hospitals and research institutions worldwide to further develop its technology and expand its reach. Some of these partners include the National Cancer Centre Singapore, Mayo Clinic, Stanford University School of Medicine, etc.
Lucence's vision is to become a global leader in liquid biopsy tests for cancer diagnosis and treatment. The company aims to make its tests accessible to patients worldwide by partnering with healthcare providers, insurance companies, etc.
In conclusion, Lucence Diagnostics Pte Ltd is a game-changer in the field of cancer diagnosis and treatment. Its ultrasensitive and non-invasive liquid biopsy tests offer a faster, more accurate, and less invasive alternative to traditional tissue biopsy methods. With its proprietary technology AmpliMARK™ combined with NGS and AI algorithms, Lucence is poised to revolutionize how we diagnose cancers at an early stage when they are still treatable.
lucencedx.com
